



**EORTC Melanoma Group Young
Investigator Meeting**

Berlin 15th October 2015

Programme

11.00-11.05 Welcome and introduction

11:05-11:20 **A Distinct Role for Eosinophil and Neutrophil Granulocytes in Patients with Advanced Melanoma Receiving Selective BRAF Inhibitors** Cindy Franklin

11:20-11:40 **Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: upfront markers for ipilimumab treatment in metastatic melanoma** Chiara Martinoli

11:40-12:00 **Predictors of toxicity for metastatic melanoma patients treated with ipilimumab** Sara Valpione

12:00-12:20 **Cell-free DNA V600E measurements during vemurafenib therapy of metastatic melanoma patients** Katarzyna Kozak

12:20-12:40 **p53 reactivation by PRIMA-1[Met] (APR-246) sensitises [V600E/K]BRAF melanoma to vemurafenib: from bench to a phase I/II trial** Mohammad Krayem

12.40-13.00 Summary and final questions from morning session

13.00-14.00 LUNCH

14:00-14:20 **How much the behaviour of physician is far from the evidence reported on pregnancy and melanoma: a European-wide survey** Simone Ribero

14:20-14:40 **Time Interval Between Primary Melanoma Excision and Sentinel Node Biopsy Does Not Affect Survival – Results From a Large Multicenter Cohort** Charlotte Oude Ophuis

14:40-15:00 **Clinical Biomarkers in Stage 3-B Melanoma** Max Madu

15.00-15.20 **Ultrasound of the Sentinel Node in Melanoma Patients: Echo Free Island (EFI) is a Discriminatory Morphologic Feature for Node Positivity** Charlotte Oude Ophuis

15.20-15.30 Summary and close